Learn More
OBJECTIVE The aim of this study was to assess the ability of pantoprazole to maintain gastric acid suppression in patients with gastroesophageal reflux disease who are switched from an oral (p.o.) to an intravenous (i.v.) dosage form. METHODS A total of 65 patients with gastroesophageal reflux disease were administered either 40 or 20 mg of p.o.(More)
OBJECTIVE The purpose of this study was to compare the gastric acid inhibitory ability of increasing doses of intravenous (i.i.) pantoprazole with that of i.v. famotidine and placebo. Pentagastrin was infused continuously in healthy subjects as a model for patients with Zollinger-Ellison syndrome. METHODS Pentagastrin (1 microg/kg/h) was infused to(More)
Pantoprazole, an irreversible proton pump inhibitor, may be administered with cisapride, a prokinetic agent. As increased cisapride concentrations may result in longer electrocardiogram (ECG) QTc intervals, a crossover study was conducted in healthy subjects to evaluate the oral pharmacokinetic interaction between cisapride (20 mg) and pantoprazole (40 mg).(More)
BACKGROUND Patients with impaired hepatic function usually require gastric acid-suppressant therapy but are at increased risk for drug interactions and may require dosage adjustments. The proton pump inhibitor pantoprazole is rapidly absorbed and eliminated, primarily by cytochrome P450 (CYP) 2C19 isozymes. OBJECTIVE This study sought to determine whether(More)
We present a unique case of a 49-year-old woman presenting with a bilateral chylothorax sustained after minor injury. This condition developed secondarily to minor neck injury which resulted in left side cervical swelling. First treatment was conservative. Surgical intervention was nevertheless necessary to remove a cervical cyst contiguous with the(More)
  • 1